Abstract
Abstract
A sensitive and accurate LC-MS/MS method was developed and validated for the simultaneous quantification of rivaroxaban (RIV) and sitagliptin (SIT) in rat plasma using apixaban as internal standard (IS). An Agilent Eclipse plus C18 column (2.1 × 100 mm, 3.5 µm, Agilent) was used for chromatographic separation with isocratic elution. Multiple reaction monitoring (MRM) using positive-ion ESI mode to monitor ion transitions of m/z 436.8→144.9 for RIV, m/z 407.7→173.8 for SIT, m/z 459.8→442.8 for IS. The procedure of method validation included selectivity, linearity, precision, accuracy, matrix effect, extraction recovery and stability were conducted according to the guidelines of EMA and FDA. The results indicated that no obvious drug-drug interactions occurred might be owing to their differences in metabolic pathways.
Funder
Basic Research plan of Natural Science of Shaanxi Province, China
General Special Scientific Research Project of Education Department of Shaanxi Provincial Government, Shaanxi Province, China
College of Medicine, Yan'an University
National teaching team of rehabilitation technology of China
Reference38 articles.
1. Renoprotective effects of the dipeptidyl peptidase-4 inhibitor sitagliptin: a review in type 2 diabetes;Mega;J. Diabetes Res.,2017
2. Minimizing the risk of bleeding with NOACs in the elderly;Kundu;Drugs & Aging,2016
3. Investigation of the profile and kinetics of degradation of rivaroxaban using HPLC, TLC-densitometry and LC/MS/MS: application to pre-formulation studies;Abdallah;Bull. Fac. Pharm. Cairo Univ.,2015
4. Sitagliptin: a review in type 2 diabetes;Scott;Drugs,2017
5. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes;Hanefeld;Curr. Med. Res. Opin.,2007
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献